CNS Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
CNSP CNS Pharmaceuticals Inc
FLJ FLJ Group Ltd
UPST Upstart Holdings Inc
CPSI Computer Programs and Systems Inc
TKNO Alpha Teknova Inc
BTM Bitcoin Depot Inc
RC Ready Capital Corp
NEOV NeoVolta Inc
SCHL Scholastic Corp
SIDU Sidus Space Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Value

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Closing Price: $1.17

Day's Change: -0.05 (-4.10%)

Bid: --

Ask: --

B/A Size: --

Day's High: 1.28

Day's Low: 1.17

Volume (Heavy Day) Volume: 32,187 10-day average volume: 25,502: 32,187

September 07, 2023
8:47 am ET	CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM) Completion of enrollment of study on track by end of 2023 Topline data results from interim analysis also on track to announce by end of 2023 HOUSTON, TX / ACCESSWIRE / September 7, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or...(Accesswire)
September 05, 2023
8:47 am ET	CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference Live webcast presentation on Wednesday, September 13th at 10:30 AM ET HOUSTON, TX / ACCESSWIRE / September 5, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development...(Accesswire)
August 14, 2023
8:37 am ET	CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy Data presented at the 2023 SNO/ASCO CNS Cancer Conference Berubicin currently being evaluated in an ongoing potentially pivotal study for the treatment of Glioblastoma Multiforme (GBM) with topline data from interim analysis expected before...(Accesswire)
7:36 am ET	CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones Continued rapid pace of enrollment with ~75% of expected patients now enrolled in ongoing potentially pivotal study evaluating Berubicin for the treatment of GBM Topline data from interim analysis from ongoing Berubicin potentially pivotal...(Accesswire)
August 03, 2023
8:15 am ET	CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference Live moderated webcast fireside chat on August 3rd at 11:35 AM ET HOUSTON, TX / ACCESSWIRE / August 3, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of...(Accesswire)
8:01 am ET	CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Company continued to see rapid progression and acceleration of enrollment with 180 patients enrolled to date across 46 clinical trial sites, globally Completion of enrollment of study expected by end of 2023 (Accesswire)
July 27, 2023
9:05 am ET	CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference HOUSTON, TX / ACCESSWIRE / July 27, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and...(Accesswire)
July 06, 2023
12:01 pm ET	JTC Team Announces Presenting Company Line-Up for the Virtual Investor Summer Spotlight Series - Event taking place on July 11th, 12th, and 13th - - Live video webcast with moderated interactive discussion with participating companies - - Access the event at www.virtualinvestorco.com - (Accesswire)
July 05, 2023
8:45 am ET	CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series Live moderated video webcast on Tuesday, July 11th at 12:00 PM ET HOUSTON, TX / ACCESSWIRE / July 5, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel...(Accesswire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and